Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial -
Frontiers | Beyond Conventional: The New Horizon of Targeted Therapy for the Treatment of Advanced Non Small Cell Lung Cancer
Cancers | Free Full-Text | Responses to the Tepotinib in Gastric Cancers with MET Amplification or MET Exon 14 Skipping Mutations and High Expression of Both PD-L1 and CD44
Tepotinib in patients with non-small cell lung cancer with high-level MET amplification detected by liquid biopsy | Scholarly Publications
Tepotinib overcomes MET-mediated sotorasib resistance in vivo Antitumor... | Download Scientific Diagram
Contemporary Developments in MET-Selective Kinase Inhibitors in Advanced Non–Small-Cell Lung Cancer
Cancers | Free Full-Text | Responses to the Tepotinib in Gastric Cancers with MET Amplification or MET Exon 14 Skipping Mutations and High Expression of Both PD-L1 and CD44
Tepotinib in patients with non-small cell lung cancer with high-level MET amplification detected by liquid biopsy: VISION Cohort
MET Exon 14 Skipping in NSCLC | TEPMETKO® (tepotinib) HCP
Cancers | Free Full-Text | Companion Diagnostics and Predictive Biomarkers for MET-Targeted Therapy in NSCLC
PPD02.02 Tepotinib + Gefitinib in Patients with EGFR-Mutant NSCLC with MET Amplification (METamp): Final Analysis of INSIGHT - Journal of Thoracic Oncology
MET Exon 14 Skipping in NSCLC | TEPMETKO® (tepotinib) HCP
Brain penetration and efficacy of tepotinib in orthotopic patient-derived xenograft models of MET-driven non-small cell lung cancer brain metastases - ScienceDirect
Tepotinib Demonstrates Durable Benefit With High-Level MET Amplification
Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial -
Molecular and Clinical Profile of Patients with NSCLC with METex14... | Download Scientific Diagram
View of Tepotinib (Tepmetko) | Canadian Journal of Health Technologies
MET Exon 14 Skipping Alterations in NSCLC: Current Understanding and Therapeutic Advances - touchONCOLOGY
Tepotinib granted FDA priority review for METex14 NSCLC | BLU Ampersand, Inc.
MET and SHP2 Blockade Inhibit the Proliferation and Growth of Cells in... | Download Scientific Diagram
Contemporary Developments in MET-Selective Kinase Inhibitors in Advanced Non–Small-Cell Lung Cancer
Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation | Journal of Hematology & Oncology | Full Text
Matching-Adjusted Indirect Comparison (MAIC) of Tepotinib with Other MET Inhibitors for the Treatment of Advanced NSCLC with MET Exon 14 Skipping Mutations | Advances in Therapy
Cancers | Free Full-Text | The Development and Role of Capmatinib in the Treatment of MET-Dysregulated Non-Small Cell Lung Cancer—A Narrative Review
